Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Evolution, Not Revolution, Marks Progress In Targeted Oncology Therapy – AACR

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

The American Association for Cancer Research’s second annual Cancer Progress Report makes the case that oncology progression is more a process of refinement than breakthrough right now.

Advertisement

Related Content

Are The 90s Back? Oncologics Drove FDA’s 2012 Novel Approval Count To 15-Year High
Oncologics Drove FDA’s 2012 Novel Approval Count To 15-Year High
Ariad’s Leukemia Drug Iclusig Sails Through FDA In Less Than 3 Months
Ariad’s Leukemia Drug Iclusig Sails Through FDA In Less Than 3 Months
Novartis Brings “Disruptive Innovation” To Clinical Trials
New Drugs Build On Personalized Medicine Momentum In Lung Cancer
Pazdur’s Tale Of Two Targeted Therapies
GlaxoSmithKline Deals One-Two Punch With BRAF/MEK Pair
Synchronized Regulation: Tandem Approvals Of Xalkori, Diagnostic Required Considerable Coordination
Innovation Pays: Priority Drugs Drove Novel 2011 Approvals To New Heights

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS004956

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel